Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
P276
- Development stage
- Phase 2
- Lead developer
- Piramal
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
P276 is a code name referring to a small molecule cyclin-dependent kinase (CDK) inhibitor, specifically P276-00, developed as an anticancer agent. The drug was designed to inhibit cyclin D1/CDK4 and CDK9, which are involved in cell cycle regulation and transcription. P276 has been evaluated in preclinical and early clinical studies for various solid tumors and hematological malignancies. It works by blocking the phosphorylation of the retinoblastoma protein and inhibiting transcription of key survival-related genes, thereby inducing growth arrest and apoptosis in cancer cells.
- Other names
- P276-00P-276-00P 276-00riviciclib hydrochloride
02
Targets
CDK1 (Cyclin-dependent kinase 1)P-TEFb (Positive transcription elongation factor b)CDK4 (Cyclin-dependent kinase 4)CDK9 (Cyclin-dependent kinase 9)
Beyond the preview
Go deeper on P276.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on P276.